Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

ImmunoTech Biopharm’s CAR-T-19 Earns Breakthrough Therapy Designation for B-ALL Treatment

Fineline Cube Dec 12, 2024

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced receiving...

Company Deals

Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China

Fineline Cube Dec 12, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...

Company Deals

EOSVISION Ltd Secures Series A Funding to Advance Ophthalmic Implant Development

Fineline Cube Dec 12, 2024

Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug

Fineline Cube Dec 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...

Company

VIVA Biotech Expands Global Footprint with New Boston Branch

Fineline Cube Dec 12, 2024

China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...

Company Deals

Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions

Fineline Cube Dec 12, 2024

Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...

Company Deals

Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments

Fineline Cube Dec 12, 2024

Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...

Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Company Drug

AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study

Fineline Cube Dec 12, 2024

UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...

Company Drug

Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates

Fineline Cube Dec 12, 2024

Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...

Company Deals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Fineline Cube Dec 12, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...

Company Deals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...

Company Drug

Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study

Fineline Cube Dec 12, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...

Policy / Regulatory

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Fineline Cube Dec 11, 2024

The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions...

Company Deals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Fineline Cube Dec 11, 2024

Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech...

Company Drug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

Fineline Cube Dec 11, 2024

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...

Company Deals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Fineline Cube Dec 11, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot...

Company Drug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Fineline Cube Dec 11, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...

Company Drug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Fineline Cube Dec 11, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...

Posts pagination

1 … 274 275 276 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.